Exelixis, Inc.

NASDAQ:EXEL

Biotechnology

Healthcare
$68.29 +0.65%

+$0.34 today

Market cap
$17.17B
Beta
0.43
P/E (TTM)
16.3
EPS (TTM)
$3.23
52W Low $33.76High $53.93

Volume 1.82M

Average 2.55M

EXEL Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Exelixis, Inc.NASDAQ: EXEL

Net Income · Q2 FY2026 · quarter ended Jul 2026

Net income grows, but more slowly than its trailing trend

Q2 FY2026 net income of $212.05M rose 14.7% year over year, behind the +42.9% change in trailing-twelve-month net income. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at +62.5% a year.

Context

  • Net income amounted to 33.7% of revenue in FY2025, up 9.7 pp from a year earlier.
  • Net income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 12 analysts of $1.04B (+33.0%) for the fiscal year ending Jan 2027, a slowdown from the +50.1% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJul 2026
$212.05M+0.8% QoQ
Last fiscal yearJan 2026
$782.57M+50.1% YoY
LTMJul 2026
$860.62M+42.9% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.7%+17.2%+2.5 pp
1 year+50.1%+33.0%-17.2 pp
3-year CAGR+62.5%+17.2%-45.3 pp
5-year CAGR+16.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
782.57M USD
Year-over-year change
+50.1%
4-year CAGR
+35.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How EXEL compares with its peers on the latest reported figures

  • EXEL's LTM Jul 2026 net income of $860.62M is the 5th largest of the 8 companies compared; the peer median is $466.88M.
  • Its year-over-year change of +42.9% is the 5th highest of 7, against a peer median of +101.4%.
  • Net income amounts to 35.3% of revenue for EXEL, versus a peer median of 52.6%.
EXEL Competitors Peer median
Net Income for EXEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AZNAstraZeneca PLCLTM Sep 2026$11.82B +15.4%+59.9%19.0%
RVMDRevolution Medicines, Inc.LTM Jun 2026$1.77B +117.8%+65.7%—
INCYIncyte CorporationLTM Jun 2026$1.61B +85.1%+55.7%27.7%
GMABGenmab A/SLTM Jun 2026$861.1M —-48.4%20.8%
EXELExelixis, Inc.LTM Jul 2026$860.62M +42.9%+62.5%35.3%
HCMHUTCHMED (China) LimitedLTM Jun 2025$466.88M +1212.4%—77.5%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$364.23M +879.7%—121.5%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$243.25M -26.6%+24.1%112.0%
Peer median (excluding EXEL) $466.88M+101.4%+55.7%52.6%

Competitors are the stored peer set for EXEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Jan 2025
FY2025
Jan 2026
Net Income231.06M182.28M207.77M521.27M782.57M
Depreciation & Amortization13.63M20.88M25.72M28.8M29.06M
Deferred Income Tax46.53M(60.36M)(133.21M)(59.46M)126.24M
Stock-Based Compensation119.82M107.57M106.35M93.84M112.98M
Change in Working Capital(39.01M)(12.8M)(13.97M)(13.45M)(191.2M)
Accounts Receivables(122.32M)66.85M(22.62M)(27.95M)(21.4M)
Inventory(13.21M)(11.68M)(12.98M)5.45M12.23M
Accounts Payables55.09M23.36M50.11M(21.89M)(50.15M)
Other Working Capital41.43M(91.32M)(28.48M)30.93M(131.87M)
Other Non-Cash Items28.78M125.04M140.68M128.98M24.62M
Operating Cash Flow400.8M362.61M333.32M699.97M884.27M
Capital Expenditures(64.23M)(138.46M)(162.97M)(66.19M)(39.93M)
Acquisitions (Net)00000
Purchases of Investments(1.36B)(1.45B)(902.47M)(927.91M)(632.5M)
Sales of Investments1.38B1.06B1.04B877.31M1.02B
Other Investing Activities(10M)(110.75M)(122.5M)(37.75M)(31.5M)
Investing Cash Flow(42.88M)(524.41M)(26.96M)(116.78M)350.44M
Debt Repayment00000
Common Stock Issued023.89M33.45M61.85M49.14M
Common Stock Repurchased00(550.38M)(652.03M)(947.51M)
Dividends Paid00000
Other Financing Activities(14.8M)(23.3M)(29.12M)(38.63M)(71.22M)
Financing Cash Flow(14.8M)586K(546.05M)(628.81M)(969.59M)
Effect of Forex Changes00000
Net Change in Cash343.12M(161.21M)(239.68M)(45.62M)265.11M
Free Cash Flow336.58M224.16M170.36M633.79M844.34M

Exelixis, Inc.

NASDAQ:EXEL

Intrinsic Alpha fair value

Locked

Current Price

$68.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.